Literature DB >> 6426075

Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis.

A Penketh, M E Hodson, H Gaya, J C Batten.   

Abstract

A randomised controlled open comparison of azlocillin and gentamicin versus carbenicillin and gentamicin was carried out in patients with cystic fibrosis who were chronically infected with Pseudomonas aeruginosa. The clinical response was assessed by measurements of pulmonary function and of the patients' feelings of wellbeing scored on a visual analogue scale. The sputum penetration of the antibiotics used was also studied. The two groups of 10 patients were similar in terms of age, sex, and pulmonary function at entry to the trial. Both regimens produced significant improvement in pulmonary function over 10 days. The mean FEV1 in the azlocillin group increased from 1206 to 1760 ml (p less than 0.001). In the carbenicillin group the mean FEV1 increased from 1116 to 1619 ml (p less than 0.001). Significant improvements in peak expiratory flow rate, forced vital capacity, and score on the visual analogue scale were also seen but there was no significant difference between the antibiotic regimens. Despite high serum concentrations the sputum penetration of the antibiotics was poor.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6426075      PMCID: PMC459787          DOI: 10.1136/thx.39.4.299

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  [Azlocillin--a new penicillin against Pseudomonas aeruginosa and other gram-negative bacteria].

Authors:  H B König; K G Metzger; R P Mürmann; H A Offe; P Schacht; W Schröck
Journal:  Infection       Date:  1977       Impact factor: 3.553

Review 3.  The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis.

Authors:  M I Marks
Journal:  J Pediatr       Date:  1981-02       Impact factor: 4.406

4.  Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature.

Authors:  P A di Sant'agnese; P B Davis
Journal:  Am J Med       Date:  1979-01       Impact factor: 4.965

5.  Pseudomonas colonization in cystic fibrosis. A study of 160 patients.

Authors:  L L Kulczycki; T M Murphy; J A Bellanti
Journal:  JAMA       Date:  1978-07-07       Impact factor: 56.272

6.  Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins.

Authors:  R Wise; A P Gillett; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

7.  Pseudomonas infections of the lung treated with azlocillin. Microbiology, pharmacokinetics, clinic.

Authors:  G K Daikos; H Giamarellou; K Hadjipolydorou; K Kanellakopoulou
Journal:  Arzneimittelforschung       Date:  1979

8.  New cause of penicillin treatment failure.

Authors:  P Barnes; P M Waterworth
Journal:  Br Med J       Date:  1977-04-16

9.  Pharmacokinetics of azlocillin in children with cystic fibrosis.

Authors:  T Bergan; H Michalsen
Journal:  Arzneimittelforschung       Date:  1979

10.  Bacteremia in patients with cystic fibrosis.

Authors:  M M McCarthy; M H Rourk; A Spock
Journal:  Clin Pediatr (Phila)       Date:  1980-11       Impact factor: 1.168

View more
  8 in total

Review 1.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Amanda Plummer; Martin Wildman; Tim Gleeson
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

Review 2.  High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.

Authors:  F Sörgel; U Stephan; H G Wiesemann; B Gottschalk; C Stehr; M Rey; H B Böwing; H C Dominick; M Geldmacher von Mallinckrodt
Journal:  Infection       Date:  1987       Impact factor: 3.553

3.  Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.

Authors:  T Jensen; S S Pedersen; N Høiby; C Koch
Journal:  Eur J Clin Microbiol       Date:  1987-12       Impact factor: 3.267

Review 4.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

5.  Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms. British Thoracic Society Research Committee.

Authors: 
Journal:  Thorax       Date:  1985-05       Impact factor: 9.139

6.  Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.

Authors:  M J Smith; L O White; H Bowyer; J Willis; M E Hodson; J C Batten
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

7.  Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load?

Authors:  Pieter Deschaght; Petra Schelstraete; Leen Van Simaey; Marleen Vanderkercken; Ann Raman; Linda Mahieu; Sabine Van Daele; Frans De Baets; Mario Vaneechoutte
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

Review 8.  Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.

Authors:  Matthew N Hurley; Andrew P Prayle; Patrick Flume
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.